SEATTLE, WA -- (MARKET WIRE) -- December 12, 2006 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that the company has licensed two patents in its broad portfolio of AAV intellectual property to Amsterdam Molecular Therapeutics B.V. (AMT). The non-exclusive license to U.S. patents #6,759,237 and #7,105,345, which were issued to the University of Pennsylvania and exclusively licensed to Targeted Genetics, provides AMT with the rights to use AAV1 in the development and commercialization of therapeutic products for treating type I and type V lipoprotein lipase (LPL) deficiencies. AMT currently is conducting Phase II trials of AMT-011, an AAV1-based therapy for type I LPL deficiency, and anticipates launching the product in the European Union in 2008. LPL deficiency in humans is a severe and debilitating disease associated with extremely high serum triglyceride concentrations, high morbidity, and increased mortality.
